Replies to post #173457 on Biotech Values

[biomaven0]

>> Close to a half of pts getting Xtandi got chemo comparing to a the placebo-arm.
Consequently, the MDVN claim that Xtandi postponed the chemo by 17 months is outright misleading.<<

This was a blinded trial. When people progressed quickly, they had a good chance of getting put on chemo. If you look at the radiological progression slide (an amazing 0.19 HR), you will see that virtually all the quick progressors were on placebo.

We don't know yet to what extent the slow progressors got put on chemo - that data isn't yet mature.

Peter

[DewDiligence]

The totality of MDVN’s PREVAIL data is so compelling that it hardly seems to matter if one or more secondary endpoints don’t stand up to additional scrutiny.